Abstract:
This presentation offers a comprehensive overview of the extensive body of research accumulated over several decades in the field of magnetic hyperthermia as a modality for cancer treatment. Despite the significant investment of time, resources, and scientific effort, this promising field has yet to produce a single successful clinical trial, a sobering reality that demands serious reflection and a fundamental reassessment of current approaches. The persistent failure to translate laboratory findings into clinically viable therapies can be largely attributed to a critical gap in understanding: the precise mechanisms by which tumor cells are destroyed when magnetic nanoparticles are subjected to an applied alternating magnetic field (AMF). Without a clear and validated mechanistic framework, the optimization of treatment parameters has remained largely empirical, limiting the field's ability to design effective, reproducible, and safe therapeutic protocols.
Against this backdrop, the presentation introduces the speaker's recent and ongoing research efforts, which are specifically aimed at confronting these long-standing challenges head-on. By rigorously investigating the biophysical and biochemical interactions that govern nanoparticle behavior under AMF conditions, the speaker's work seeks to lay the scientific groundwork necessary for AMF-driven magnetic nanoparticles to finally meet the stringent requirements of clinical cancer therapy. This work speaks directly to unresolved questions at the intersection of materials science, biomedical engineering, and oncology. The speaker will present a forward-looking perspective on what the field has overlooked, what foundational knowledge is still lacking, and what experimental and theoretical advances are needed to achieve reliable, non-thermal cancer cell death under AMF, moving beyond hyperthermia toward a broader and more mechanistically grounded therapeutic paradigm.
